UBS Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

UBS Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57.5M	Sell	450,200 -348,600	-44%	-$43.5M	0.01%	1510
2025 Q4	$97.4M	Buy	798,800 +140,100	+21%	+$16.1M	0.02%	1033
2025 Q3	$66M	Sell	658,700 -113,300	-15%	-$10.2M	0.01%	1374
2025 Q2	$64M	Sell	772,000 -6,200	-0.8%	-$495K	0.01%	1291
2025 Q1	$63.1M	Sell	778,200 -72,000	-8%	-$6.44M	0.01%	1274
2024 Q4	$76.6M	Buy	850,200 +618,300	+267%	+$59.9M	0.01%	1100
2024 Q3	$22.9M	Sell	231,900 -274,300	-54%	-$27M	0.01%	1716
2024 Q2	$46.9M	Sell	506,200 -16,400	-3%	-$1.47M	0.01%	1075
2024 Q1	$49.6M	Sell	522,600 -589,100	-53%	-$54.7M	0.01%	1040
2023 Q4	$99.3M	Sell	1,111,700 -302,400	-21%	-$22.5M	0.03%	575
2023 Q3	$103M	Sell	1,414,100 -357,200	-20%	-$28.5M	0.04%	492
2023 Q2	$147M	Buy	1,771,300 +907,900	+105%	+$75.9M	0.05%	358
2023 Q1	$65.8M	Buy	863,400 +522,000	+153%	+$43.3M	0.02%	647
2022 Q4	$28.3M	Buy	341,400 +118,900	+53%	+$9.63M	0.01%	1175
2022 Q3	$17.6M	Sell	222,500 -205,000	-48%	-$17.3M	0.01%	1360
2022 Q2	$31.8M	Buy	427,500 +140,000	+49%	+$10.5M	0.01%	1029
2022 Q1	$25.8M	Sell	287,500 -1,087,800	-79%	-$100M	0.01%	1250
2021 Q4	$154M	Buy	1,375,300 +650,200	+90%	+$78.4M	0.04%	419
2021 Q3	$91.2M	Buy	725,100 +307,600	+74%	+$39.6M	0.03%	569
2021 Q2	$56.5M	Sell	417,500 -313,100	-43%	-$41.2M	0.02%	782
2021 Q1	$99.1M	Buy	730,600 +317,600	+77%	+$47.6M	0.03%	526
2020 Q4	$58.1M	Buy	413,000 +108,000	+35%	+$13.8M	0.02%	715
2020 Q3	$34M	Sell	305,000 -46,700	-13%	-$5.24M	0.01%	859
2020 Q2	$39.4M	Sell	351,700 -300,900	-46%	-$29.6M	0.02%	717
2020 Q1	$50.5M	Sell	652,600 -209,900	-24%	-$18.6M	0.02%	535
2019 Q4	$82M	Sell	862,500 -205,900	-19%	-$17.8M	0.03%	526
2019 Q3	$81.5M	Buy	1,068,400 +693,000	+185%	+$57.6M	0.03%	469
2019 Q2	$32.9M	Buy	375,400 +285,900	+319%	+$24.4M	0.01%	902
2019 Q1	$8.1M	Sell	89,500 -99,600	-53%	-$8.47M	﹤0.01%	1832
2018 Q4	$13.6M	Buy	189,100 +139,100	+278%	+$11.2M	0.01%	1352
2018 Q3	$4.79M	Sell	50,000 -6,700	-12%	-$650K	﹤0.01%	2384
2018 Q2	$5.4M	Buy	56,700 +6,700	+13%	+$616K	﹤0.01%	2276
2018 Q1	$4.39M	Sell	50,000 -61,200	-55%	-$5.59M	﹤0.01%	2437
2017 Q4	$9.44M	Buy	111,200 +1,200	+1%	+$101K	﹤0.01%	1771
2017 Q3	$9.52M	Sell	110,000 -2,100	-2%	-$168K	﹤0.01%	1654
2017 Q2	$8.65M	Buy	112,100 +2,100	+2%	+$149K	﹤0.01%	1664
2017 Q1	$7.63M	Sell	110,000 -259,300	-70%	-$17.4M	﹤0.01%	1719
2016 Q4	$21.9M	Buy	369,300 +40,000	+12%	+$2.47M	0.01%	969
2016 Q3	$21.8M	Buy	+329,300	New	+$20.4M	0.01%	921
2016 Q1	–	Sell	-112,800	Closed	-$7.92M	–	8250
2015 Q4	$7.92M	Sell	112,800 -911,000	-89%	-$62.1M	0.01%	1578
2015 Q3	$63.7M	Buy	1,023,800 +1,023,500	+341,167%	+$80.7M	0.05%	390
2015 Q2	$25K	Hold	300	–	–	﹤0.01%	6672
2015 Q1	$23K	Sell	300 -30,900	-99%	-$2.16M	﹤0.01%	6861
2014 Q4	$1.94M	Buy	+31,200	New	+$1.78M	﹤0.01%	2935

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

UBS Group's XBI Position: Q1 2026 in Review

UBS Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 19% in Q1 2026, buying an estimated $71.1M and bringing the position to 3,546,650 shares worth $453M. The position accounts for 0.07% of the portfolio, ranked #291.

UBS Group first reported a position in XBI in Q4 2014 and has held it in 46 quarters since. The position peaked at $738M in Q1 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

UBS Group held 3,546,650 shares of State Street SPDR S&P Biotech ETF worth $453M as of Q1 2026.
UBS Group bought 569,529 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $71.1M.
State Street SPDR S&P Biotech ETF made up 0.07% of UBS Group's portfolio in Q1 2026, its #291 holding.
UBS Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and has held it in 46 quarters since.
UBS Group's State Street SPDR S&P Biotech ETF position peaked at $738M in Q1 2019.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.